Malaria vaccines are prophylactic vaccines against Plasmodium parasites which cause malaria in humans. Malaria vaccines can help prevent malaria infection in populations living in malaria-endemic regions. There is a high demand for vaccines to control and eliminate malaria which infects hundreds of millions annually and kills over 400,000 people each year, mainly children in Africa. Several candidate malaria vaccines are under development which target different life stages of the parasite's complex life cycle. GlaxoSmithKline's RTS,S/AS01 is currently the most advanced malaria vaccine candidate.
The Global Malaria Vaccines Market is estimated to be valued at USD 620.0 Mn in 2025 and is expected to exhibit a CAGR of 12.7% over the forecast period 2025 to 2032. Key Takeaways Key players operating in the malaria vaccines market are GlaxoSmithKline plc, Sanaria. GlaxoSmithKline plc holds the leading position in the market with its candidate vaccine RTS,S/AS01 currently being pilot deployed in selected African countries after regulatory approval in 2015.
There is a significant Malaria Vaccines Market Size demand for novel and effective malaria vaccines from pharmaceutical companies, governments and public health organizations to control the spread of the disease. The market provides opportunities for development of new vaccine candidates targeting the hypnozoite liver stage, pre-erythrocytic and sexual blood stages of malaria's complex life cycle.
Major players are expanding their manufacturing and partnerships with African countries to deploy vaccines across malaria endemic regions and accelerate eliminating the disease globally. Key opportunities in the market include development of new vaccine modalities such as DNA vaccines and recombinant protein based subunit vaccines.
Vector based technologies also offer potential for designing multi-antigen vaccines providing protection against various Plasmodium strains. Partnerships between global organizations such as WHO, drug developers and African governments are facilitating global expansion of malaria vaccines across disease hotspots. Regulatory approval and financial support is driving the commercial deployment of first generation vaccine RTS,S/AS01 in Africa.
Market drivers
The high disease burden of malaria is driving the demand for effective vaccines. According to WHO, malaria infects about 229 million people annually worldwide. Lack of effective interventions makes disease elimination challenging in many regions. Vaccines can help overcome limitations of current anti-malarial tools and accelerate control programs. Support from global health organizations to develop novel vaccines is positively impacting the market.
Market restraints
Developing effective malaria vaccines is extremely challenging due to the complex parasite life cycle. Poor understanding of protective immune responses is hindering vaccine design. Large phase III efficacy trials required before approval demands significant investments putting limitations on early stage developers. Limited commercial viability of vaccines in developing countries acts as a deterrent for manufacturers.
Segment Analysis
The malaria vaccines market is segmented based on vaccine type, technology, and end-use. Based on vaccine type, pre-erythrocytic vaccine segment dominated the market and accounted for the largest market share in 2024. The high infection rate of malaria parasites in liver cells makes pre-erythrocytic vaccines highly effective in preventing the disease. The RTS,S/AS01 vaccine developed by GlaxoSmithKline plc is the only vaccine approved for use till date and falls under this segment. By technology, the whole particle vaccines segment holds the highest share as RTS,S uses this technology. Whole particle vaccines contain whole, killed/live attenuated malaria parasites or fragments of the malaria parasite for inducing immune response. They mimic natural infection and provide protection against diverse strains. However, subunit/recombinant vaccines are growing at a faster rate owing to advantages such as better safety and focused immune response.
Global Analysis Regionally, the malaria vaccines market in Africa dominates others with over 60% share due to the high malaria burden in the region. As per WHO, African region accounted for over 90% of global malaria cases and deaths in 2021. Countries like Nigeria, Democratic Republic of the Congo, Uganda and Burkina Faso reported the highest number of cases. Availability of national malaria control programs coupled with initiatives by global health organizations to develop effective vaccines makes Africa the fastest growing regional market. On the other hand, Asia Pacific region is poised to witness higher growth during the forecast period backed by rising investments in vaccine development projects by governments and presence of major players in countries like India.
Get this Report in Japanese Language- マラリアワクチン市場
Get this Report in Korean Language- 말라리아 백신 시장
About Author-
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Known for her strong SEO background, she skillfully blends SEO strategies with insightful content. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
